Why AST SpaceMobile, Inc. (ASTS) Went Up On Friday
We recently published a list of In this article, we are going to take a look at where AST SpaceMobile, Inc. (NASDAQ:ASTS) stands against other Friday's top performers.
The stock market ended the trading week on a strong note, with all major indices clocking in strong gains, as investors cheered better-than-expected non-farm payrolls last month while digesting more corporate earnings results.
The tech-heavy Nasdaq led the rally among all major indices, finishing up by 1.51 percent. The S&P 500 clocked in a 1.47-percent gain, while the Dow Jones grew by 1.39 percent.
Ten companies also mimicked the broader market optimism following impressive earnings performance and an optimistic outlook for the rest of the year. In this article, we have identified the 10 top performers on Friday and detailed the reasons behind their gains.
To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume.
An aerial view of a communications satellite in orbit, beaming its signal down to Earth.
AST SpaceMobile Inc. jumped by 14.77 percent on Friday to finish at $26.42 each as investors repositioned portfolios ahead of the results of its earnings performance in the first three months of the year.
According to the company, it will release the results of its earnings performance after market close on May 12, 2025, where investors will be looking out for its updated outlook and more partnership cues.
Just recently, AST SpaceMobile, Inc. (NASDAQ:ASTS) clinched a new deal with the US National Science Foundation (NSF), its major facilities, and the broader US astronomy, to closely collaborate on mitigating any potential impact on ground-based astronomical facilities.
The agreement includes adopting measures recommended by the International Astronomical Union's Dark and Quiet Skies initiative, including reducing satellite brightness and providing accurate, real-time satellite positioning data to observatories.
Overall, ASTS ranks 7th on our list of Friday's top performers. While we acknowledge the potential of ASTS as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ASTS but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
Cellectar Biosciences announces 1-for-30 reverse stock split
Cellectar Biosciences (CLRB) announced a one-for-thirty reverse stock split of the company's common stock, par value $0.00001, which will become effective on Tuesday, June 24. The company's common stock will continue to trade under its current trading symbol, CLRB, on Nasdaq on a split-adjusted basis when the market opens on Tuesday, June 24, with the new CUSIP number 15117F880. As a result of the Reverse Stock Split, every 30 shares of the company's pre-split common stock issued and outstanding will be automatically reclassified into one new share of the company's common stock. The Reverse Stock Split will reduce the number of shares of common stock issued and outstanding from 54,361,197 shares to approximately 1,812,040. There will be no change to the number of authorized shares or the par value per share. The Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholder's percentage ownership interest. As a result of the Reverse Stock Split, the number of shares of common stock available for issuance under the company's equity incentive plans will be proportionately affected. Confident Investing Starts Here:
Business Upturn
2 hours ago
- Business Upturn
Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering
New Taipei City, Taiwan, June 18, 2025 (GLOBE NEWSWIRE) — Jyong Biotech Ltd. (Nasdaq: MENS) (the 'Company'), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced the closing of its initial public offering (the 'Offering') of 2,666,667 ordinary shares (the 'Ordinary Shares') at a public offering price of $7.5 per share for aggregate gross proceeds of approximately $20 million, before deducting underwriting discounts and other offering expenses. The Ordinary Shares commenced trading on Nasdaq Global Market on June 17, 2025, under the ticker symbol 'MENS'. The Offering closed on June 18, 2025. The Company has granted the underwriters an option, exercisable within 45 days from the date of the final prospectus, to purchase up to an additional 400,000 Ordinary Shares at the public offering price, less underwriting discounts, to cover over-allotments, if any. The Company intends to use the net proceeds from the Offering for (i) funding the additional Phase III trials of MCS-2 (API-2) and the new drug application of MCS-2 (40%); (ii) funding earlier phase trials if the Company is unable to demonstrate comparability (25%); (iii) funding the Phase II trial of PCP (10%); (iv) funding the Phase I clinical trial of IC (5%), and (v) general corporate purposes (20%). The Offering was conducted on a firm commitment basis. Joseph Stone Capital, LLC acted as sole underwriter for the Offering (the 'Underwriter'). Sichenzia Ross Ference Carmel LLP acted as U.S. securities counsel to the Company, and VCL Law LLP acted as U.S. securities counsel to the Underwriter, in connection with the Offering. A registration statement on Form F-1 (File No. 333-277725) relating to the Offering, as amended, was previously filed with the U.S. Securities and Exchange Commission (the 'SEC') and was declared effective by the SEC on June 16, 2025. The Offering was made only by means of a prospectus. Copies of the prospectus related to the Offering may be obtained from Joseph Stone Capital, LLC by standard mail to Joseph Stone Capital, LLC, 585 Stewart Ave., Suite L60-C, Garden City, NY 11530, or via email at [email protected] or by telephone at +1 (888) 302-5548. In addition, a copy of the final prospectus relating to the Offering, dated June 16, 2025, can also be obtained via the SEC's website at Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Jyong Biotech Ltd. Headquartered in Taiwan, Jyong Biotech a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, MCS-2, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers' health needs and seeks to be a valuable business organization that is held in high esteem by the public. For more information, please visit: Forward-Looking Statement This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as 'may, 'will, 'intend,' 'should,' 'believe,' 'expect,' 'anticipate,' 'project,' 'estimate' or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, the Company's statements regarding the intended use of the proceeds from the Offering. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the 'Risk Factors' section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. For more information, please contact: UnderwriterJoseph Stone Capital, LLC (888) 302-5548 [email protected]
Business Upturn
2 hours ago
- Business Upturn
Willis launches Zest Insurance, a digital revolution for Australian SMEs
MELBOURNE, Australia, June 18, 2025 (GLOBE NEWSWIRE) — Willis, a WTW business (NASDAQ: WTW), today launches Zest Insurance, a cutting-edge digital insurance platform tailored specifically for small and medium enterprises (SMEs) in Australia. Zest Insurance represents a bold step forward in the digital transformation of SME insurance. It offers a seamless, fast and intuitive online experience backed by expert broker support. Designed to meet the evolving needs of modern business owners, Zest Insurance empowers SMEs to purchase, manage and renew their insurance policies entirely online. James Baum, Head of Pacific, WTW says: 'The launch of Zest Insurance comes at a pivotal time for the Australian SME market. With 97% of businesses having 20 or fewer employees, the platform is poised to serve a vast and growing segment of the market. Zest Insurance aims to bridge the gap between traditional insurance models and the digital expectations of modern SME owners.' Brent Lehmann, Head of Commercial & Affinity, Pacific at Willis, adds: 'SMEs are the backbone of the Australian economy, yet many still face outdated, complex processes when it comes to insurance. They increasingly demand convenience, speed and tailored insurance solutions. Zest Insurance is our answer to that challenge, bringing together digital convenience and trusted expertise in one powerful platform. It aims to make purchasing business insurance more straightforward for small business owners.' The Australian SME market, valued at over AUD 9 billion in gross written premium, has been slower to adopt digital insurance solutions compared to global counterparts. Zest Insurance aims to close that gap by offering: A fully digital customer journey – from insurance quote to bind, renewal, and policy management, all conducted online. – from insurance quote to bind, renewal, and policy management, all conducted online. Industry-specific insurance solutions – with one dedicated insurer per industry to ensure tailored coverage to protect businesses. – with one dedicated insurer per industry to ensure tailored coverage to protect businesses. User-friendly design – intuitive forms and interfaces built to enhance and simplify the customer experience. – intuitive forms and interfaces built to enhance and simplify the customer experience. Insurance broker support on demand – expert advice available when needed, ensuring confidence and clarity. Zest Insurance will be available initially to businesses in the administration and support services industry, including bookkeepers, payroll services, management and marketing consultants, market research firms and more, with plans to expand industry offerings in future phases. Zest Insurance policies for this first industry will be exclusively underwritten by Chubb, a world leader in insurance. James adds: 'We've built Zest Insurance to be more than just a platform. It's a new way of thinking about SME insurance. It's about simplicity, transparency and putting the customer first. Together, we're setting a new standard for SME insurance, starting in Australia.' For more information, visit: About WTW At WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk and capital. Leveraging the global view and local expertise of our colleagues serving 140 countries and markets, we help organizations sharpen their strategy, enhance organizational resilience, motivate their workforce and maximize performance. Working shoulder to shoulder with our clients, we uncover opportunities for sustainable success—and provide perspective that moves you. Learn more at Media contact Clara Goh: +65 6958 2542 [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
